Logical Therapeutics, a developer of drugs for inflammatory conditions, says that it has closed a $16.9 million in a Series C round of funding, according to a press release. Xconomy reported last week that the Waltham, MA-based firm had raised $10 million of a planned $16.9 million round of financing, based on online records from the SEC. The company did not comment at the time, and it wasn’t clear from the records who invested in the financing. Now Logical says it’s closed on the full amount, and that SV Life Sciences led the round, which included investments from Burrill & Co., Novo A/S, and Novitas Capital.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
